News Mission Therapeutics raises £60m to advance novel ‘DUB’ drug... UK biotech company Mission Therapeutics has raised £60 million to invest into its drug discovery and development programme.
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
